The Role of Daclizumab in Balancing Resources for Inpatient and Outpatient Transplant Services

Abstract

Transplant professionals have the dual responsibility of achieving acceptable clinical outcomes and controlling costs. One approach transplant centers have used to control transplant-related costs has been to decrease patients' length of stay, and thus it has decreased significantly in the last 6 years. This reduction in resource consumption has been accomplished by increased efficiency in providing transplantation services, expanding the number of outpatient services available, and integrating new technologies. Future cost containment measures by payers, especially Medicare, will continue to require that transplant centers manage resources and meet financial objectives while achieving acceptable clinical outcomes.

Daclizumab, a new immunosuppressive drug, is used as an example in this article, which assesses its value in helping meet resource management and financial goals.

Get full access to this article

View all access options for this article.

References

Naylor

Brooten

Campbell

. Comprehensive discharge planning and home follow-up of hospitalized elders: A randomized clinical trial. JAMA. 1999;281:613–620.

*StraMarTec, Inc. Research Survey: Transplant Center Reimbursement Survey. Shrewsbury, NJ: StraMarTec, Inc; 1996.

100% Medpar Inpatient Hospital Data. Baltimore, Md: Health Care Financing Administration, Bureau of Data Management and Strategy, US Department of Health and Human Services. Available at: http://www.hcfa.gov. Accessed February 9, 1999.

Balanced Budget Act of 1997 (Pub L No. 105-33). Medicare and Medicaid provisions, subtitle E, chap 1 § 4401. Available at: http://www.hcfa.gov. Accessed January 12, 2000.

Health Care Financing Administration. Fee schedule for physicians' services. In: Careers Manual (part 3, chap 15 § 15501, codes 99201–99499). Baltimore, Md: US Department of Health and Human Services. Available at: http://www.hcfa.gov. Accessed January 12, 2000.

Evaluation and management services guidelines. In: Current Procedural Terminology 1999 (Professional Edition). 4th ed. Chicago, Ill: American Medical Association; 1999:1–9.

1998 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data: 1988–1997. Rockville, Md: US Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation; Richmond, Va: United Network for Organ Sharing; 1998.

Halamandaris

. Caring thoughts. Caring. October 1985;4(10):80.

Lemkin

. Infusion therapy: The lifeline of home health care. Independent Living. March 1992;7(1):29.

10.

Bartucci

Moir

Schulak

Hricik

. Home therapy with OKT3: A safe and cost-effective approach to the treatment of acute allograft rejection. J Transplant Coordination. 1993;3(suppl 1):22–26.

11.

Medicare Intermediary Manual. Baltimore, Md: Health Care Financing Administration, US Department of Health and Human Services; 1999.

12.

Zenapax (Daclizumab) sterile concentrate for injection [package insert]. Nutley, NJ: Roche Pharmaceuticals/Hoffmann-La Roche Inc; 1999.

13.

Orthoclone OKT3 sterile solution [package insert]. Raritan, NJ: Ortho Biotec Inc; 1995.

14.

Periodic Safety Update Report on (Zenapax). Basel, Switzerland: F Hoffmann-La Roche Ltd; 1999.